Topic:

Venture Capital

Latest Headlines

Latest Headlines

Targeting ALS, GlaxoSmithKline and Avalon seed another build-to-buy startup

Partners GlaxoSmithKline and Avalon Ventures have seeded a 7th startup in their company-building collaboration, lining up $10 million for a new effort to treat ALS.

Flagship launches another microbiome biotech with $35M and a focus on cancer

Flagship Ventures, the group behind microbiome success story Seres Therapeutics, is delving further into gut science with a new startup that aims to treat cancer by harnessing the power of the body's many bacterial tenants.

Gates, Hopp back $110M megaround for CureVac's mRNA work

The Bill & Melinda Gates Foundation joined German billionaire Dietmar Hopp in a venture syndicate that is injecting a whopping $110 million of fresh funds into CureVac, a German mRNA biotech which has now garnered some $330 million in support.

Marquee VCs back a $40M round for Crinetics' acromegaly drug

A group of marquee venture investors has joined forces to back a $40 million Series A for Crinetics Pharmaceuticals, an early-stage biotech in San Diego that has been working on a next-gen oral treatment for acromegaly.

Biotech IPOs are staggering as the bulls begin to fade back

Third Rock startup MyoKardia staggered onto Nasdaq on Wednesday, pricing its IPO at $10 a share--a deep, bargain basement discount from the hefty range it set for itself.

Frazier unveils a $262M pure-play biotech venture fund

After 24 years in the venture investing game, Frazier Healthcare Partners is unveiling a new, $262 million fund that will be the very first that it is devoting exclusively to life sciences companies. And the startup experts say they've never seen a better time to back new biotechs concentrating primarily on new drug development.

After a big-money Allergan deal, Taris returns with a $32M round and a new pipeline

Massachusetts' Taris Biomedical is getting back into R&D after flipping its lead asset to Allergan in a $587.5 million deal, raising $32 million to advance new treatments for bladder disease.

AIT pushes ahead with plans for $40M Nasdaq IPO

Advanced Inhalation Therapies (AIT) has become the latest biotech to push ahead with plans to float on Nasdaq in the face of mounting evidence that investors are cooling on such offerings. The company is hoping its mix of Wall Street experience in the C-suite and upcoming clinical trial data readouts will make it an attractive proposition to investors.

Insiders help Strongbridge limp to a downsized $25M IPO

Strongbridge Biopharma has struggled through choppy conditions to complete a $25 million (€22 million) listing on Nasdaq. The rare disease player pulled off the dramatically downsized IPO by relying heavily on the support of existing shareholders, who snapped up 80% of all the shares sold.

Acacia postpones £150M IPO as London market for big listings dries up

Less than two weeks after Shield Therapeutics pulled the plug on its £110 million ($170 million) IPO, Acacia Pharma has backed away from its plan to raise £150 million by listing on the London Stock Exchange.
'